Overview

Effect of Denosumab on Cellular Biomarkers in the Human Breast

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab